The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index; none of the 16 sources its claims cite is checked for support yet.
Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life -- a double-blind, placebo-controlled study: Randomised clinical trial: B. bifidum MIMBb75 in IBS
Open accessAbstract
BACKGROUND: Recent research suggests that an imbalance of the intestinal microbiota and a dysfunctional intestinal barrier might trigger irritable bowel syndrome (IBS). As probiotics have been reported to restore the intestinal microbiota and the gut barrier, the therapeutic potential of probiotics within IBS became of strong interest. AIM: To assess the efficacy of Bifidobacterium bifidum MIMBb75 in IBS. METHODS: A total of 122 patients were randomised to receive either placebo (N=62) or MIMBb75 (N=60) once a day for 4 weeks. The severity of IBS symptoms was recorded daily on a 7-point Likert scale. RESULTS: MIMBb75 significantly reduced the global assessment of IBS symptoms by -0.88 points (95% CI: -1.07; -0.69) when compared with only -0.16 (95% CI: -0.32; 0.00) points in the placebo group (P<0.0001). MIMBb75 also significantly improved the IBS symptoms pain/discomfort, distension/bloating, urgency and digestive disorder. The evaluation of the SF12 sum scores showed a significant gain in quality of life within the bifidobacteria group. Furthermore, adequate relief was reported by 47% of the patients in the bifidobacteria and only by 11% of the patients in the placebo group (P<0.0001). Overall responder rates were 57% in the bifidobacteria group but only 21% in the placebo group (P=0.0001). MIMBb75 was well tolerated and adverse events were not different from placebo. CONCLUSIONS: Bifidobacterium bifidum MIMBb75 effectively alleviates global IBS and improves IBS symptoms simultaneously with an improvement of quality of life. Considering the high efficacy of MIMBb75 in IBS along with the good side-effect profile, MIMBb75 is a promising candidate for IBS therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
17 Own result · 13 Not checked yet · 9 Own method · 6 Own interpretation · 1 No basis given
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The study population has mild to moderate IBS symptoms as evidenced by the indicated SGA-baseline values.”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > DISCUSSION AND CONCLUSION
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The reduction persisted during wash-out phase (2.33 in the bifidobacteria group vs. 3.47 in the placebo group, P < 0.0001).”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Secondary endpoints
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and distension ⁄ bloating by )0.92 points (95% CI: )1.15; )0.69) vs. )0.21(95% CI: )0.37; )0.05) in the placebo group (P < 0.0001) during the treatment.”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Secondary endpoints
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The evaluation of the SGA on a weekly basis showed a significant benefit for patients within the bifidobacteria group for every single week starting the second week of treatment till the end of the study (Figure 3).”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Bifidobacterium bifidum
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Additionally, no severe adverse events have been recorded in either group.”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Adverse events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“First of all, the study population was not large enough for a subgroup analysis of IBS subtypes.”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > DISCUSSION AND CONCLUSION
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The allocation was blinded to both patients and site staff.”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Study design
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The ability of specific strains to adhere well to intestinal cells may play a pivotal role in altering the intestinal microbiota and increasing the intestinal barrier, which might be of significant value especially in the treatment of IBS.”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > INTRODUCTION
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Moreover, B. bifidum MIMBb75 also significantly improved the quality of life.”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > DISCUSSION AND CONCLUSION
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“While some studies might have missed to show efficacy due to small sample size and randomisation errors, several different probiotic strains did repeatedly show no significant improvement in IBS.[20][21][22][23][24]”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > DISCUSSION AND CONCLUSION
What the sources say
- Not checked yetcites [20][21][22][23][24]
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 28
- The quote only partly states this claim. 2
- Probably not a substantial claim. 11
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Bowel movement satisfaction (digestive disorder) decreased from 3.89 to 2.44 in the bifidobacteria group vs. 3.69 to 3.47 in the placebo group (P = 0.0002) after treatment.”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Secondary endpoints
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Overall responder rates were 57% in the bifidobacteria group and only 21% in the placebo group (P = 0.0001).”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Treatment responders
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At the end of treatment, 43% of the patients in the bifidobacteria group achieved adequate relief compared with only 8% in the placebo group (P < 0.0001).”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Global efficacy at physician site
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Only 36 adverse events were reported with suspected relation to the study product, 13 in the placebo and 23 in the treatment group, but no significant differences could be detected in the side-effects profile of B. bifidum MIM-Bb75 vs. placebo”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Adverse events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Urgency was significantly reduced by )0.67 points (95% CI: )0.86; )0.48) vs. )0.21(95% CI: )0.35; )0.07) in the placebo group (P = 0.0001) during the treatment but not during the wash-out phase.”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Secondary endpoints
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“MIMBb75 significantly reduced the global assessment of IBS symptoms by )0.88 points (95% CI: )1.07; )0.69) when compared with only )0.16 (95% CI: )0.32; 0.00) points in the placebo group (P < 0.0001).”
- Also stated in: § Bifidobacterium bifidum · plain
“MIMBb75 significantly improved global IBS symptoms by )0.88 points (95% CI: )1.07; )0.69) (from 2.95 in the run in phase to 2.07 in the treatment phase) compared with only )0.16 points (95% CI: )0.32; 0.00) (from 2.79 in the run in phase to 2.63 in the treatment phase) in the placebo group (P < 0.0001) using the 7-point Likert scale.”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Abstract
plaindirectn = 122 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § Bifidobacterium bifidum · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Bifidobacterium bifidum MIMBb75 showed a significant reduction of pain ⁄ discomfort by )0.82 points (95% CI: )1.01; )0.63) vs. )0.18(95% CI: )0.35; )0.01) in the placebo group (P < 0.0001)”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Secondary endpoints
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No effects could be detected for frequency of bowel movement and feeling of incomplete bowel evacuation (Figure 4).”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Secondary endpoints
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The difference between the treatment arms was only a little bit less pronounced when considering only the symptom 'pain ⁄ discomfort' where responder rates were calculated to be 48% in the bifidobacteria and only 24% in the placebo group (P = 0.008)”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Treatment responders
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Physical health sum significantly changed by 3.99 in the bifidobacteria group and by only 1.08 in the placebo group compared with baseline (P = 0.0185).”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Health-related quality of life
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Mental health sum significantly changed by 5.78 in the bifidobacteria group and by only 1.58 in the placebo group compared with baseline (P = 0.0083).”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Health-related quality of life
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The reduction persisted during the wash-out phase.”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Secondary endpoints
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one. The quote only partly states this claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“A total of 132 patients were included into the study and 122 patients were successfully randomised to receive either placebo (N = 62) or B. bifidum MIMBb75 (N = 60).All randomised patients were analysed for intent to treat (N = 122).”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Subjects
plainn = 122- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The primary analysis was based on the intent-to-treat population where all successfully randomised patients were included.Missing post-baseline values were imputed by the baseline value for the primary target criterion and these patients were evaluated as nonresponders”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Statistical analysis
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The prospectively defined primary efficacy variable was the subject's global assessment of IBS symptoms using a 7-point Likert scale.”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Endpoint definitions
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The treatment was allocated according to a computer-generated blocked randomisation list with a block size of 4.”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Study design
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“This study was performed as a prospective, multi-centre, randomised, double-blind, placebo-controlled, two-arm nutritional study.”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Study design
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
In the paper
“Based on published data, 17 a difference of 0.6 points in the SGA of IBS symptoms between B. bifidum MIMBb75 and placebo on the 7-point Likert scale was anticipated”
- Also stated in: § Sample size estimation. · plain
“With these assumptions, a Wilcoxon-Mann-Whitney test with a two-sided significance level of a = 0.05 and a power of 1)b = 0.8, a sample size of 47 patients per group was required.”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Sample size estimation.
What the sources say
- Not checked yetcites [17] Whorwell, 2006, Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome, Am J Gastroenterol source
plainn = 132- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
- Also stated in: § Sample size estimation. · plain
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The block size was not disclosed to the investigators.”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Study design
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“In terms of baseline characteristics, there were no significant differences between the groups”
- Also stated in: § Baseline characteristics · boosted
“Demographics were well balanced between the treatment groups”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Baseline characteristics
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one. The quote only partly states this claim.
- Also stated in: § Baseline characteristics · boosted
None of the sources cited for this claim have been checked yet.
In the paper
“Several studies have observed altered intestinal microbiota with a significant lack of bifidobacteria 25,26 and a dysfunctional intestinal barrier in IBS patients.”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > DISCUSSION AND CONCLUSION
What the sources say
- Not checked yetcites [25] Kerckhoffs, 2009, Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients, World J Gastroenterol source
- Not checked yetcites [26] Si, 2004, Intestinal microecology and quality of life in irritable bowel syndrome patients, World J Gastroenterol source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Guglielmetti et al. showed that BopA, a surface protein, is directly involved in the adhesion to Caco-2 cells.15”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Probiotic preparation
What the sources say
- Not checked yetcites [15] Guglielmetti, 2008, Implication of an outer surface lipoprotein in adhesion of bifidobacterium bifidum to caco-2 cells, Appl Environ Microbiol source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“BopA has been found in several strong adhesive B. bifidum strains, indicating that BopA might be an indicator of strong adherence.”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Probiotic preparation
What the sources say
- Not checked yetcites [15] Guglielmetti, 2008, Implication of an outer surface lipoprotein in adhesion of bifidobacterium bifidum to caco-2 cells, Appl Environ Microbiol source
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“A total of 16 RCTs were included in the analysis.Of those, exclusively one Bifidobacterium strain showed efficacy for the improvement of IBS symptoms in two appropriately designed studies.4”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > DISCUSSION AND CONCLUSION
What the sources say
- Not checked yetcites [4] Brenner, 2009, The utility of probiotics in the treatmet of irritable bowel syndrome: a systematic review, Am J Gastroenterol source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Considering the high efficacy of MIMBb75 in IBS along with the good side-effect profile, MIMBb75 is a promising candidate for IBS therapy.”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: Conventional medical treatment for IBS is unsatisfactory.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In this study, B. bifidum MIMBb75 significantly improved global IBS as well as its related symptoms such as pain ⁄ discomfort, distension ⁄ bloating and digestive disorders compared with placebo.”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > DISCUSSION AND CONCLUSION
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Recent research suggests that an imbalance of the intestinal microbiota with a significant reduction of bifidobacteria and a dysfunctional intestinal barrier with subsequent bacterial translocation may contribute to the development of IBS and its symptoms.”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > INTRODUCTION
What the sources say
- Not checked yetcites [5][6]][7][8][9]
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Additionally B. bifidum MIMBb75 showed considerably more adhesion to the Caco-2 monolayer in the presence of fucose and mannose and less when B. bifidum MIMBb75 grew in Oxgall bile salts compared with standard environmental conditions.”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Probiotic preparation
What the sources say
- Not checked yetcites [16] Guglielmetti, 2009, Study of the adhesion of bifidobacterium bifidum MIMBb75 to human intestinal cell lines, Curr Microbiol source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“However, the efficacy of probiotics is strongly strain specific and only certain strains might be able to improve IBS and its symptoms.[12][13][14]”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > INTRODUCTION
What the sources say
- Not checked yetcites [12][13][14]
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Additionally, gut mucosal barrier disruption has been proven to be associated with bacterial translocation and inflammatory conditions.[4][5][6]”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > DISCUSSION AND CONCLUSION
What the sources say
- Not checked yetcites [4][5][6]
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Bifidobacterium bifidum MIMBb75 effectively alleviates global IBS and improves IBS symptoms simultaneously with an improvement of quality of life.”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Abstract
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: Conventional medical treatment for IBS is unsatisfactory.
In the paper
“The colonisation strategy of this bacterium could be influenced by several factors varying along the gastrointestinal tract, such as the presence of specific sugars and bile salts and the pH, likely supporting adhesion of B. bifidum MIMBb75 to distal sites of the gut.16”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Probiotic preparation
What the sources say
- Not checked yetcites [16] Guglielmetti, 2009, Study of the adhesion of bifidobacterium bifidum MIMBb75 to human intestinal cell lines, Curr Microbiol source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“It has been stated that the imbalance of the microbiotic composition may lead to a different fermentation pattern, especially with increased hydrogen production resulting in bloating.28,29”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > DISCUSSION AND CONCLUSION
What the sources say
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“As probiotics have been reported in several studies to restore the intestinal microbiota and gut barrier as well as hinder bacterial translocation, the therapeutic potential of probiotics in IBS has become of strong interest.10,11”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > INTRODUCTION
What the sources say
- Not checked yetcites [10] Alvares-Olmos, 2001, Probiotic agents and infectious diseases: a modern perspective on a traditional therapy, Clin Infect Dis source
- Not checked yetcites [11] Salminen, 1996, Clinical uses of probiotics for stabilizing the gut mucosal barrier: successful strains and future challenges, Antonie Van Leeuwenhoek source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper relies on this without support.
Conventional medical treatment for IBS is unsatisfactory.
“As the conventional medical treatment of IBS is unsatisfactory, we have evaluated the efficacy of B. bifidum MIMBb75 in IBS in a double blind, placebo-controlled multi-centre study.”
The paper relies on this without support.
No probiotic strain has yet been shown to significantly alleviate IBS while also improving quality of life.
“Additionally, to our knowledge, no probiotic strain could show to significantly alleviate irritable bowel syndrome and simultaneously improve the quality of life.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The second study did not detect any effects of the specific probiotic treatment on the frequency of bowel movements and feelings of incomplete evacuation.56”
From Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice - an evidence-based international guide (2013) · cites this paper as [56]
In the citing paper
“For example, one study reported that Bifidobacterium bifidum MIMBb75 was beneficial for improving global IBS symptoms, bloating and aspects of health-related quality of life (physical and mental health), but not for frequency of bowel movement and feeling of incomplete bowel evacuation.56”
From Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice - an evidence-based international guide (2013) · cites this paper as [56]
In the citing paper
“In some of the better quality trials bifidobacteria, such as Bifidobacterium infantis 35624,215 224 241 Bifidobacterium lactis DN 173010208 225 and Bifidobacterium bifidum MIMBb75,226 seem to be advantageous and in others probiotic mixtures appear to be useful.214 229 233”
From Intestinal microbiota in functional bowel disorders: a Rome foundation report (2013) · cites this paper as [226]
In the citing paper
“Other smaller studies reported some beneficial effects with other probiotic strains including Bifidobacterium animalis DN-173 010 (74), Bifidobacterium bifidum MIMBb75 (72), Lactobacillus plantarum 299V (117), Saccharomyces boulardii (37), and combination of Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 (144) and multispecies probiotic mixtures (71, 87, 88).”
From Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome (2013) · cites this paper as [72]
In the citing paper
“Specific probiotics help reduce bloating/distension in some patients with IBS Moderate [147,149-150,155-156,168-170, 174-177,179-183]”
From Gut microbiota role in irritable bowel syndrome: New therapeutic strategies (2016) · cites this paper as [155]
In the citing paper
“With specific probiotics, improvement of symptoms has been shown to lead to improvement in some aspects of health-related quality of life Moderate [147,150,152,155,169-170,174,176-177,179-180,183-184,186]”
From Gut microbiota role in irritable bowel syndrome: New therapeutic strategies (2016) · cites this paper as [155]
In the citing paper
“Specific probiotics may help reduce constipation in some patients with IBS Low [155-156,183,185]”
From Gut microbiota role in irritable bowel syndrome: New therapeutic strategies (2016) · cites this paper as [155]
Citations
Cites
Longstreth, G. F., Thompson, W. G., Chey, W. D., Houghton, L. A., Mearin, F., & Spiller, R. C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.061 · Cited by 4,856
O’Mahony, L., McCarthy, J., Kelly, P., Hurley, G., Luo, F., Chen, K., O’Sullivan, G. C., Kiely, B., Collins, J. K., Shanahan, F., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.11.050 · Cited by 1,448
Kassinen, A., Krogius-Kurikka, L., Mäkivuokko, H., Rinttilä, T., Paulin, L., Corander, J., Malinen, E., Apajalahti, J., & Palva, A. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.005 · Cited by 1,002
Whorwell, P. J., Altringer, L., Morel, J., Bond, Y., Charbonneau, D., O'Mahony, L., Kiely, B., Shanahan, F., & Quigley, E. M. M. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00734.x · Cited by 799
Eradication of Small Intestinal Bacterial Overgrowth Reduces Symptoms of Irritable Bowel Syndrome
Pimentel, M., Chow, E. J., & Lin, H. C. (2000) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.03368.x · Cited by 780
Pimentel, M., Chow, E. J., & Lin, H. C. (2003) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.07234.x · Cited by 670
SILK, D. B. A., DAVIS, A., VULEVIC, J., TZORTZIS, G., & GIBSON, G. R. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03911.x · Cited by 551
Salminen, S., Isolauri, E., & Salminen, E. (1996) · Antonie van Leeuwenhoek · doi:10.1007/bf00395941 · Cited by 406
Kim, H. J., Vazquez Roque, M. I., Camilleri, M., Stephens, D., Burton, D. D., Baxter, K., Thomforde, G., & Zinsmeister, A. R. (2005) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2005.00695.x · Cited by 400
GUYONNET, D., CHASSANY, O., DUCROTTE, P., PICARD, C., MOURET, M., MERCIER, C. ‐., & MATUCHANSKY, C. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03362.x · Cited by 365
Cited by
Sorted by citations
Probiotics, prebiotics and synbiotics- a review
Pandey, K. R., Naik, S. R., & Vakil, B. V. (2015) · Journal of Food Science and Technology · doi:10.1007/s13197-015-1921-1 · Cited by 1,350
Intestinal microbiota in functional bowel disorders: a Rome foundation report
Simrén, M., Barbara, G., Flint, H. J., Spiegel, B. M. R., Spiller, R. C., Vanner, S., Verdu, E. F., Whorwell, P. J., & Zoetendal, E. G. (2013) · Gut · doi:10.1136/gutjnl-2012-302167 · Cited by 939
Ford, A. C., Quigley, E. M. M., Lacy, B. E., Lembo, A. J., Saito, Y. A., Schiller, L. R., Soffer, E. E., Spiegel, B. M. R., & Moayyedi, P. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.202 · Cited by 747
Diet-Induced Dysbiosis of the Intestinal Microbiota and the Effects on Immunity and Disease
Brown, K., DeCoffe, D., Molcan, E., & Gibson, D. L. (2012) · Nutrients · doi:10.3390/nu4081095 · Cited by 700
Ford, A. C., Moayyedi, P., Lacy, B. E., Lembo, A. J., Saito, Y. A., Schiller, L. R., Soffer, E., Spiegel, B. M. R., & Quigley, E. M. M. (2014) · The American Journal of Gastroenterology · doi:10.1038/ajg.2014.187 · Cited by 664
Ford, A. C., Harris, L. A., Lacy, B. E., Quigley, E. M. M., & Moayyedi, P. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15001 · Cited by 619
Petra, A. I., Panagiotidou, S., Hatziagelaki, E., Stewart, J. M., Conti, P., & Theoharides, T. C. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.04.002 · Cited by 592
An overview of the last advances in probiotic and prebiotic field
Saad, N., Delattre, C., Urdaci, M. C., Schmitter, J., & Bressollier, P. (2012) · LWT · doi:10.1016/j.lwt.2012.05.014 · Cited by 540
Vinderola, G., Sanders, M. E., & Salminen, S. (2022) · Foods · doi:10.3390/foods11081077 · Cited by 425
Stress and the Microbiota–Gut–Brain Axis in Visceral Pain: Relevance to Irritable Bowel Syndrome
Moloney, R. D., Johnson, A. C., O’Mahony, S. M., Dinan, T. G., Meerveld, B. G., & Cryan, J. F. (2015) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12490 · Cited by 412
Systematic review with meta-analysis: The efficacy of probiotics in inflammatory bowel disease
Derwa, Y., Gracie, D. J., Hamlin, P. J., & Ford, A. C. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14203 · Cited by 393
American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome
Ford, A. C., Moayyedi, P., Chey, W. D., Harris, L. A., Lacy, B. E., Saito, Y. A., & Quigley, E. M. M. (2018) · American Journal of Gastroenterology · doi:10.1038/s41395-018-0084-x · Cited by 388
Didari, T. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i10.3072 · Cited by 356
Turroni, F., Ventura, M., Buttó, L. F., Duranti, S., O’Toole, P. W., Motherway, M. O., & van Sinderen, D. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1318-0 · Cited by 336
Gut microbiota role in irritable bowel syndrome: New therapeutic strategies
Distrutti, E., Monaldi, L., Ricci, P., & Fiorucci, S. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i7.2219 · Cited by 320
Carroll, I. M., Ringel-Kulka, T., Keku, T. O., Chang, Y.-H., Packey, C. D., Sartor, R. B., & Ringel, Y. (2011) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00154.2011 · Cited by 292
New Approaches for Bacteriotherapy: Prebiotics, New-Generation Probiotics, and Synbiotics
Patel, R., & DuPont, H. L. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ177 · Cited by 282
Abouelela, M. E., & Helmy, Y. A. (2024) · Microorganisms · doi:10.3390/microorganisms12030430 · Cited by 269
Recent Development of Probiotic Bifidobacteria for Treating Human Diseases
Chen, J., Chen, X., & Ho, C. L. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.770248 · Cited by 259
Genomic Encyclopedia of Type Strains of the Genus Bifidobacterium
Milani, C., Lugli, G. A., Duranti, S., Turroni, F., Bottacini, F., Mangifesta, M., Sánchez, B., Viappiani, A., Mancabelli, L., Taminiau, B., et al. (2014) · Applied and Environmental Microbiology · doi:10.1128/aem.02308-14 · Cited by 251
Ferrario, C., Taverniti, V., Milani, C., Fiore, W., Laureati, M., De Noni, I., Stuknyte, M., Chouaia, B., Riso, P., & Guglielmetti, S. (2014) · The Journal of Nutrition · doi:10.3945/jn.114.197723 · Cited by 228
Self-citationClarke, G. A., Cryan, J. F., Dinan, T. G., & Quigley, E. M. M. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04965.x · Cited by 221
Hungin, A. P. S., Mulligan, C., Pot, B., Whorwell, P., Agréus, L., Fracasso, P., Lionis, C., Mendive, J., Philippart de Foy, J.-M., Rubin, G., et al. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12460 · Cited by 212
World Gastroenterology Organisation Global Guidelines: Probiotics and Prebiotics
Guarner, F., Sanders, M. E., Szajewska, H., Cohen, H., Eliakim, R., Herrera-deGuise, C., Karakan, T., Merenstein, D., Piscoya, A., Ramakrishna, B., et al. (2024) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002002 · Cited by 209
Meta-analysis: antibiotic therapy for small intestinal bacterial overgrowth
Shah, S. C., Day, L. W., Somsouk, M., & Sewell, J. L. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12479 · Cited by 207
Andresen, V., Gschossmann, J., & Layer, P. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(20)30056-x · Cited by 206
Gut memories: Towards a cognitive neurobiology of irritable bowel syndrome
Kennedy, P. J., Clarke, G., Quigley, E. M. M., Groeger, J. A., Dinan, T. G., & Cryan, J. F. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.07.001 · Cited by 193
Probiotics in the management of irritable bowel syndrome and inflammatory bowel disease
Whelan, K., & Quigley, E. M. M. (2013) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e32835d7bba · Cited by 190
Bifidobacteria—Insight into clinical outcomes and mechanisms of its probiotic action
Sarkar, A., & Mandal, S. (2016) · Microbiological Research · doi:10.1016/j.micres.2016.07.001 · Cited by 190
The influence of the human microbiome and probiotics on cardiovascular health
Ettinger, G., MacDonald, K., Reid, G., & Burton, J. P. (2014) · Gut Microbes · doi:10.4161/19490976.2014.983775 · Cited by 180
Zhang, Y., Li, L., Guo, C., Mu, D., Feng, B., Zuo, X., & Li, Y. (2016) · BMC Gastroenterology · doi:10.1186/s12876-016-0470-z · Cited by 180
Human-Derived Bifidobacterium dentium Modulates the Mammalian Serotonergic System and Gut–Brain Axis
Engevik, M. A., Luck, B., Visuthranukul, C., Ihekweazu, F. D., Engevik, A. C., Shi, Z., Danhof, H. A., Chang-Graham, A. L., Hall, A., Endres, B. T., et al. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2020.08.002 · Cited by 164
Varankovich, N. V., Nickerson, M. T., & Korber, D. R. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.00685 · Cited by 169
Aguilera, M., Cerdà-Cuéllar, M., & Martínez, V (2015) · Gut Microbes · doi:10.4161/19490976.2014.990790 · Cited by 162
Diet in irritable bowel syndrome: What to recommend, not what to forbid to patients!
Cozma-Petruț, A. P., Loghin, F., Miere, D., & Dumitrascu, D. L. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i21.3771 · Cited by 158
The microbiota-gut-brain axis in functional gastrointestinal disorders
De Palma, G., Collins, S. M., & Bercik, P. (2014) · Gut Microbes · doi:10.4161/gmic.29417 · Cited by 157
Hungin, A. P. S., Mitchell, C. R., Whorwell, P., Mulligan, C., Cole, O., Agréus, L., Fracasso, P., Lionis, C., Mendive, J., Philippart de Foy, J. ‐., et al. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14539 · Cited by 154
Bifidobacterium bifidum: A Key Member of the Early Human Gut Microbiota
Turroni, F., Duranti, S., Milani, C., Lugli, G. A., van Sinderen, D., & Ventura, M. (2019) · Microorganisms · doi:10.3390/microorganisms7110544 · Cited by 140
Abdulqadir, R. F., Engers, J., & Al–Sadi, R. (2023) · Current Developments in Nutrition · doi:10.1016/j.cdnut.2023.102026 · Cited by 136
AGA Technical Review on the Role of Probiotics in the Management of Gastrointestinal Disorders
Preidis, G. A., Weizman, A. V., Kashyap, P., & Morgan, R. L. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.05.060 · Cited by 137
Exploring the role of the microbiota member Bifidobacterium in modulating immune-linked diseases
O’Neill, I. J., Schofield, Z., & Hall, L. J. (2017) · Emerging Topics in Life Sciences · doi:10.1042/etls20170058 · Cited by 131
Sun, Y.-Y., Li, M., Li, Y.-Y., Li, L.-X., Zhai, W.-Z., Wang, P., Yang, X.-X., Gu, X., Song, L.-J., Li, Z., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-21241-z · Cited by 126
Efficacy of Probiotics for Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis
Zhang, T., Zhang, C., Zhang, J., Sun, F., & Duan, L. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.859967 · Cited by 125
Guglielmetti, S., Fracassetti, D., Taverniti, V., Del Bo’, C., Vendrame, S., Klimis-Zacas, D., Arioli, S., Riso, P., & Porrini, M. (2013) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf402495k · Cited by 123
Self-citationBifidobacterium bifidum as an example of a specialized human gut commensal
Turroni, F., Duranti, S., Bottacini, F., Guglielmetti, S., van Sinderen, D., & Ventura, M. (2014) · Frontiers in Microbiology · doi:10.3389/fmicb.2014.00437 · Cited by 128
Self-citationIrritable bowel syndrome and gut microbiota
Canakis, A., Haroon, M., & Weber, H. C. (2019) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000523 · Cited by 126
Modulation of microbiota as treatment for intestinal inflammatory disorders: An uptodate
Gallo, A., Passaro, G., Gasbarrini, A., Landolfi, R., & Montalto, M. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i32.7186 · Cited by 122
Frequently asked questions about the ISAPP postbiotic definition
Vinderola, G., Sanders, M. E., Cunningham, M., & Hill, C. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1324565 · Cited by 135
Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome
Ringel, Y., & Maharshak, N. (2013) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00207.2012 · Cited by 115
Ku, S., Park, M., Ji, G., & You, H. J. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17091544 · Cited by 110
Intestinal microbiota in pathophysiology and management of irritable bowel syndrome.
(2014) · PubMed Central · doi:10.3748/wjg.v20.i27.8886 · Cited by 106
New insights into the pathogenesis and treatment of irritable bowel syndrome
Oświęcimska, J. M., Szymlak, A., Roczniak, W., Girczys-Połedniok, K., & Kwiecień, J. (2017) · Advances in Medical Sciences · doi:10.1016/j.advms.2016.11.001 · Cited by 113
Effect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis
Ortiz-Lucas, M., Aurelio, T., Saz, P., & Sebastián, J. J. (2013) · Revista Española de Enfermedades Digestivas · doi:10.4321/s1130-01082013000100005 · Cited by 103
Prebiotic potential of hemp blended drinks fermented by probiotics
Nissen, L., di Carlo, E., & Gianotti, A. (2020) · Food Research International · doi:10.1016/j.foodres.2020.109029 · Cited by 102
Lactobacillus acidophilus modulates the virulence of Clostridium difficile
Yun, B., Oh, S., & Griffiths, M. W. (2014) · Journal of Dairy Science · doi:10.3168/jds.2014-7921 · Cited by 107
Rational identification of diet-derived postbiotics for improving intestinal microbiota function
Klemashevich, C. L., Wu, C., Howsmon, D. P., Alaniz, R. C., Lee, K., & Jayaraman, A. (2013) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2013.10.006 · Cited by 108
Charbonneau, D., Gibb, R. D., & Quigley, E. M. M. (2013) · Gut Microbes · doi:10.4161/gmic.24196 · Cited by 99
Horvath, A., Leber, B., Feldbacher, N., Tripolt, N. J., Rainer, F., Blesl, A., Trieb, M., Marsche, G., Sourij, H., & Stadlbauer, V. (2019) · European Journal of Nutrition · doi:10.1007/s00394-019-02135-w · Cited by 103
Gargari, G., Taverniti, V., Gardana, C., Cremon, C., Canducci, F., Pagano, I., Barbaro, M. R., Bellacosa, L., Castellazzi, A. M., Valsecchi, C., et al. (2018) · Environmental Microbiology · doi:10.1111/1462-2920.14271 · Cited by 102
Self-citationEfficacy and Safety of Probiotics in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis
Li, B., Li, L., Deng, H., Guo, J., Shu, H., & Zhang, L. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00332 · Cited by 96
Terpend, K., Possemiers, S., Daguet, D., & Marzorati, M. (2013) · Environmental Microbiology Reports · doi:10.1111/1758-2229.12056 · Cited by 88
Milani, C., Duranti, S., Lugli, G. A., Bottacini, F., Strati, F., Arioli, S., Foroni, E., Turroni, F., van Sinderen, D., & Ventura, M. (2013) · Applied and Environmental Microbiology · doi:10.1128/aem.00984-13 · Cited by 87
Niu, H.-L., & Xiao, J. (2020) · International Journal of Surgery · doi:10.1016/j.ijsu.2020.01.142 · Cited by 90
Abdominal Bloating: Pathophysiology and Treatment
Seo, A. Y., Kim, N., & Oh, D. H. (2013) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm.2013.19.4.433 · Cited by 82
Efficacy ofBifidobacterium infantis 35624in patients with irritable bowel syndrome: a meta-analysis
Yuan, F., Ni, H., Asche, C. V., Kim, M., Walayat, S., & Ren, J. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1292230 · Cited by 93
Asha, M. Z., & Khalil, S. F. H. (2020) · Sultan Qaboos University medical journal · doi:10.18295/squmj.2020.20.01.003 · Cited by 85
Mezzasalma, V., Manfrini, E., Ferri, E., Sandionigi, A., La Ferla, B., Schiano, I., Michelotti, A., Nobile, V., Labra, M., & Di Gennaro, P. (2016) · BioMed Research International · doi:10.1155/2016/4740907 · Cited by 81
Singh, R. P., Shadan, A., & Ma, Y. (2022) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-022-09992-8 · Cited by 85
McKenzie, Y. A., Thompson, J., Gulia, P., & Lomer, M. C. E. (2016) · Journal of Human Nutrition and Dietetics · doi:10.1111/jhn.12386 · Cited by 91
Layer, P., Andresen, V., Allescher, H. ‐., Bischoff, S. C., Claßen, M., Elsenbruch, S., Freitag, M., Frieling, T., Gebhard, M., Goebel‐Stengel, M., et al. (2021) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1591-4794 · Cited by 81
Probiotics in the Management of Functional Bowel Disorders
Quigley, E. M. M. (2012) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2012.08.005 · Cited by 77
Serafini, F., Strati, F., Ruas‐Madiedo, P., Turroni, F., Foroni, E., Duranti, S., Milano, F., Perotti, A., Viappiani, A., Guglielmetti, S., et al. (2013) · Anaerobe · doi:10.1016/j.anaerobe.2013.03.003 · Cited by 77
Self-citationThe potential for probiotic manipulation of the gastrointestinal microbiome
Rauch, M., & Lynch, S. V. (2011) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2011.11.004 · Cited by 80
The Role of the Human Microbiome in the Pathogenesis of Pain
Ustianowska, K., Ustianowski, Ł., Machaj, F., Gorący, A., Rosik, J., Szostak, B., Szostak, J., & Pawlik, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113267 · Cited by 77
Mazurak, N., Broelz, E. K., Storr, M., & Enck, P. (2015) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm15071 · Cited by 75
François, I., Lescroart, O., Veraverbeke, W. S., Marzorati, M., Possemiers, S., Hamer, H. M., Windey, K., Welling, G. W., Delcour, J. A., Courtin, C. M., et al. (2013) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000000285 · Cited by 72
Preston, K., Krumian, R., Hattner, J., de Montigny, D., Stewart, M., & Gaddam, S. (2018) · Beneficial Microbes · doi:10.3920/bm2017.0105 · Cited by 70
Rogha, M., Esfahani, M. Z., & Zargarzadeh, A. H. (2014) · Gastroenterology and hepatology from bed to bench. · Cited by 70
Khlevner, J., Park, Y., & Margolis, K. G. (2018) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2018.07.002 · Cited by 75
Dysbiosis in Functional Bowel Disorders
Enck, P., & Mazurak, N. (2018) · Annals of Nutrition and Metabolism · doi:10.1159/000488773 · Cited by 73
Bonfrate, L., Tack, J. F., Grattagliano, I., Cuomo, R., & Portincasa, P. (2013) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2013.799220 · Cited by 69
Yoon, J. Y., Cha, J. M., Oh, J. K., Tan, P. L., Kim, S. H., Kwak, M. S., Jeon, J. W., & Shin, H. P. (2018) · Digestive Diseases and Sciences · doi:10.1007/s10620-018-5139-8 · Cited by 68
Emerging Treatment Options in Mild to Moderate Ulcerative Colitis.
Lichtenstein, G. R., Hanauer, S. B., & Sandborn, W. J. (2015) · Europe PMC (PubMed Central) · Cited by 68
Wu, Y., Li, Y., Zheng, Q., & Li, L. (2024) · Nutrients · doi:10.3390/nu16132114 · Cited by 75
Probiotics, Nuclear Receptor Signaling, and Anti-Inflammatory Pathways
Yoon, S. S., & Sun, J. (2011) · Gastroenterology Research and Practice · doi:10.1155/2011/971938 · Cited by 67
Garofalo, C., Cristiani, C. M., Ilari, S., Passacatini, L. C., Malafoglia, V., Viglietto, G., Maiuolo, J., Oppedisano, F., Palma, E., Tomino, C., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11061701 · Cited by 68
Adaptation of bifidobacteria to the gastrointestinal tract and functional consequences
Sánchez, B., Ruíz, L., Gueimonde, M., Ruas‐Madiedo, P., & Margollés, A. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.11.004 · Cited by 66
Li, B., Lee, C. M., Filler, T., Hock, A., Wu, R., Li, Q., Chen, S., Koike, Y., Ip, W., Chi, L., et al. (2017) · Scientific Reports · doi:10.1038/srep46616 · Cited by 64
Future Modulation of Gut Microbiota: From Eubiotics to FMT, Engineered Bacteria, and Phage Therapy
Airola, C., Severino, A., Porcari, S., Fusco, W. G., Mullish, B. H., Gasbarrini, A., Cammarota, G., Ponziani, F. R., & Ianiro, G. (2023) · Antibiotics · doi:10.3390/antibiotics12050868 · Cited by 68
The Role of the Gastrointestinal Microbiota in Visceral Pain
Rea, K., O’Mahony, S. M., Dinan, T. G., & Cryan, J. F. (2016) · Handbook of experimental pharmacology · doi:10.1007/164_2016_115 · Cited by 64
Caballero, V., Estévez, M., Tomás-Barberán, F. A., Morcuende, D., Martín, I., & Delgado, J. (2022) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.2c06585 · Cited by 60
Efficacy of different probiotic protocols in irritable bowel syndrome
Ding, L., Ning, L., & Xu, G. (2019) · Medicine · doi:10.1097/md.0000000000016068 · Cited by 58
Irritable bowel syndrome: a concise review of current treatment concepts
Wall, G. C., Bryant, G. A., Bottenberg, M. M., Maki, E. D., & Miesner, A. R. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i27.8796 · Cited by 56
What’s bugging your teen?—The microbiota and adolescent mental health
McVey Neufeld, K.-A., Luczynski, P., Seira Oriach, C., Dinan, T. G., & Cryan, J. F. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.06.005 · Cited by 56
Guidelines on the management of irritable bowel syndrome
Pietrzak, A. M., Skrzydło-Radomańska, B., Mulak, A., Lipiński, M., Malecka-Panas, E. I., Reguła, J., & Rydzewska, G. M. (2018) · Gastroenterology Review · doi:10.5114/pg.2018.78343 · Cited by 60
Prebiotics, probiotics and digestive health
Balakrishnan, M., & Floch, M. H. (2012) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e328359684f · Cited by 54
Probiotics in Irritable Bowel Syndrome: A Review of Their Therapeutic Role
Kumar, L. S., Pugalenthi, L. S., Ahmad, M., Reddy, S., Barkhane, Z., & Elmadi, J. (2022) · Cureus · doi:10.7759/cureus.24240 · Cited by 59
Targeting the gut microbiota for the treatment of irritable bowel syndrome
Herndon, C. C., Wang, Y., & Lu, C. (2019) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.12154 · Cited by 57
Probiotics, Prebiotics, and Synbiotics in the Irritable Bowel Syndrome Treatment: A Review
Chlebicz-Wójcik, A., & Śliżewska, K. (2021) · Biomolecules · doi:10.3390/biom11081154 · Cited by 52
Marteau, P., Guyonnet, D., Lafaye de Micheaux, P., & Gelu, S. (2013) · Neurogastroenterology & Motility · doi:10.1111/nmo.12078 · Cited by 50
Metadata
- Authors
- Guglielmetti, S., Mora, D., Gschwender, M., & Popp, K.
- Affiliations
- University of Milan (IT)
- Corresponding author
- Guglielmetti, S.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2011-03-21
- Volume
- 33
- Issue
- 10
- Pages
- 1123-1132
- ISSN
- 0269-2813 (ISSN-L)
- OpenAlex
- W2142855591
- Semantic Scholar
- e905099c40db3ed06be733b4cdc354afe771111b
- Cited by
- 287
- References
- 30
- Citations by year
- 2026: 12 · 2025: 8 · 2024: 33 · 2023: 24 · 2022: 24 · 2021: 15 · 2020: 17 · 2019: 15 · 2018: 25 · 2017: 17 · 2016: 12 · 2015: 15 · 2014: 27 · 2013: 21 · 2012: 13
- FWCI
- 22.92
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Alimentary Pharmacology & Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Trinity's Access to Research Output (TARA) (Trinity College Dublin) (submittedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- irritable bowel syndrome, probiotics, quality of life, gut microbiota, intestinal barrier, IBS symptom severity, responder rate, tolerability
- MeSH terms
- Adult, Bifidobacterium, Double-Blind Method, Female, Humans, Intestines, Male, Middle Aged, Prospective Studies, Quality of Life, Treatment Outcome, Probiotics, Irritable Bowel Syndrome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
